-The Times of India NEW DELHI: Chances of getting killed in a road accident is the highest in Amritsar and in the country's Mercedes capital Ludhiana. Latest data on road fatalities shows that at least six people died in every 10 road crashes in these two cities in 2012 against only three in Delhi, which recorded maximum fatalities in 2012. Though Mumbai recorded the highest number of accidents among 50 million-plus cities,...
More »SEARCH RESULT
Total Matching Records found : 142
Branded medicines cost 15 times more than generic ones
-The Times of India NEW DELHI: Branded medicines cost 2-15 times more than non-branded generic medicines sold at Jan Aushadhi stores. For example, a 10-tablet strip of Diclofenac SR (100mg), a popular pain killer, costs Rs 51.91 whereas the same generic medicine costs only Rs 3.35 at Jan Aushadhi stores. An 100 ml bottle of cough syrup manufactured and marketed by drug companies costs Rs 33 while those sold at Jan Aushadhi...
More »Private care? -TK Rajalakshmi
-Frontline The National Advisory Council recommendations seem to be making a strong case for a major role for the private sector in the delivery of health care. THE recommendations for universal health coverage drawn up by the National Advisory Council (NAC), headed by United Progressive Alliance (UPA) chairperson Sonia Gandhi, push for public-private partnerships (PPPs) in the health delivery system but not for any inbuilt mechanisms for accountability. The NAC also...
More »Paying the price-Ramya Kannan
-The Hindu The much-awaited Drug (Prices Control) Order 2013 has disappointed millions of patients, as it lacks a fair formula to fix the price ceiling and leaves important drug classes out of regulation. The result: High out-of-pocket spending on medicines will continue As far as intentions go, the Drug (Prices Control) Order 2013 is aimed at making critical drugs affordable and available to the public, while preserving a rationale for manufacture by...
More »Another bitter pill for patients-Sakthivel Selvaraj
-The Hindu The current market prices are essentially over and above the actual cost of production - a difference that could run from 100 per cent to 5,600 per cent, depending upon various therapeutic categories In a liberalised market economy, do we need price controls on drugs? Policymakers and the pharmaceutical industry do not think so. They believe that price controls are an inefficient tool that distorts resource allocation, squeezes revenue, reduces...
More »
